Search the Newsreel

AbbVie (ABBV) Stock May Trade At A Premium Despite Cash Flow Upside

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie stock has delivered a strong 152.2% return over the past 5 years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value …

AbbVie (ABBV) Stock May Be 45% Undervalued On Raised 2026 Outlook

General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership

General Atlantic entities have disclosed a beneficial ownership of 5,359,727 ordinary shares in Pharvaris N.V. (PHVS), representing a 7.6% stake in the company. This disclosure was made via a Schedule 13G/A filing, with General Atlantic PH B.V. identified as the sole record holder. The …

H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress

H.C. Wainwright has reiterated a Buy rating and a $60.00 price target for Pharvaris B.V. (NASDAQ:PHVS) due to positive regulatory updates for its hereditary angioedema treatments. The FDA accepted the New Drug Application for deucrictibant IR capsule with a PDUFA action date of April …

ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease

ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results

2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical AbbVie has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per share while the index has gained …

MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT)

MPM BioImpact LLC has disclosed an amended Schedule 13G filing, reporting a beneficial ownership of 18,331,420 Ordinary Shares in DBV Technologies S.A. This represents a 6.2% stake in the company, with MPM BioImpact LLC holding sole voting and dispositive power over these shares. The …

Die AbbVie-Aktie legt nach starkem Q2-2026-Bericht und angehobener Prognose zu

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie's neuroscience franchise experienced strong growth in the first half of 2026, with sales reaching $6.1 billion, driven by key drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, and the rapid uptake of Vyalev. The company anticipates further growth from the potential approval of …

Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …

ATAI Beckley earnings beat by $0.03, revenue topped estimates

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

BV Financial (BVFL) Stock Holds Firm As Profit Growth Builds

Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions

Pharvaris N.V. President Lu Peng reported two share dispositions on August 11 and 12, 2026, totaling 226 shares. These transactions were related to shares withheld by the company to cover tax obligations arising from RSU vesting. Following these dispositions, Lu Peng's direct beneficial ownership …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

BBVA Argentina announces Second Quarter 2026 Financial Results Schedule

BUENOS AIRES, Argentina, August 13, 2026--(BUSINESS WIRE)--Banco BBVA Argentina S.A. (NYSE; BYMA; MAE: BBAR; LATIBEX: XBBAR) today announced that it will report its Second Quarter 2026 financial results. Earnings Release Thursday, Aug 27, 2026 Time: After market close Conference Call Friday, Aug 28, 2026 …

BBVA Argentina enters quiet period ahead of Aug. 27 results

BBVA Argentina (BBAR) has announced its Second Quarter 2026 financial results schedule, entering a quiet period from August 13 through August 27, 2026. The earnings release is set for after market close on Thursday, August 27, 2026, followed by a conference call on Friday, …

ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates

ProQR Therapeutics NV (NASDAQ: PRQR) reported second-quarter earnings per share that beat analyst estimates by €0.03, coming in at €-0.080 against an estimate of €-0.114. The company's revenue also surpassed expectations, reaching €8.76 million compared to the consensus estimate of €3.97 million. Despite these …

The Sharpest Exchanges From ABBV’s Earnings Call

Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Form 8K ABVC Biopharma Inc For: 12 August By Investing.com

This article reports on ABVC Biopharma Inc.'s Form 8K filing for August 12. The filing is a standard requirement for publicly traded companies to announce significant events that shareholders should know. The article provides the title of the filing and mentions the company's stock …

Pharvaris (NASDAQ:PHVS) Given New $75.00 Price Target at Citizens Jmp

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300

Wolfe has upgraded AbbVie (ABBV) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a more positive outlook on the pharmaceutical company's stock performance. The article also lists recent news and analyst actions related to AbbVie, …

AbbVie Inc. $ABBV Shares Acquired by Mission Wealth Management LP

Mission Wealth Management LP significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 119.1% in the second quarter, now holding 69,052 shares valued at $17.4 million. This move is part of a broader trend of institutional investors and hedge funds holding 70.23% of AbbVie's …

Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High - What's Next?

Pharvaris (NASDAQ:PHVS) recently hit a new 52-week high of $36.65, with a current market capitalization of $2.38 billion, despite missing its latest quarterly earnings estimate. Analyst sentiment is generally positive with a "Moderate Buy" consensus and an average price target of $50.08, though some …

Citizens raises Pharvaris stock price target to $75 on trial progress

Citizens has increased its price target for Pharvaris B.V. to $75.00 from $74.00, maintaining a Market Outperform rating, due to ongoing trial progress. The company's stock has surged 70% in the past year, and key Phase 3 CHAPTER-3 data is expected this quarter. Pharvaris …

ABVC BioPharma (ABVC) plans new equity plan and up to 6.6M-share land deal

ABVC BioPharma is seeking shareholder approval for a new 2026 Equity Incentive Plan, the ratification of 600,000 shares previously granted to advisors, and authorization to issue up to 6,638,591 shares for land acquisitions in Taiwan. The land deal is a related-party transaction with director …

How ABBV Stock Moved Away From Its Peer Group

AbbVie (ABBV) has shown strong fundamental performance with high revenue growth and operating margins, yet its stock returns significantly lag behind peers like Merck and Johnson & Johnson. This disconnect is attributed to the market pricing in future competitive threats to AbbVie's key drug …

ABVC BIOPHARMA, INC. Q2 2026: Revenue $0 EPS $(0.03) — 10-Q Summary

ABVC BIOPHARMA, INC. reported its second-quarter 2026 results, showing no revenue but a significantly narrower net loss compared to the previous year. The company posted a net loss of $736,934, an improvement from a $2,257,022 loss in Q2 2025, and diluted earnings per share …

ABVC BioPharma (ABVC) flags going concern risk after Q2 2026 cash drain

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's What Happened

Pharvaris (NASDAQ:PHVS) experienced unusually high trading volume, with 487,339 shares traded, marking a 60% increase from the previous session. The stock closed at $34.48, and analysts maintain a "Moderate Buy" rating with an average price target of $50.08 despite the company missing quarterly EPS …